Biomaterial delivery of morphogens to mimic the natural healing cascade in bone

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1257-1276

  Mehta, Manav ^a,b,c   Schmidt Bleek, Katharina ^c   Duda, Georg N ^c   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bio inspired; Biomaterials; Bone regeneration; Growth factor delivery; Spatial regulation; Temporal regulation; Tissue engineering

Indexed keywords

BIO-INSPIRED; BONE REGENERATION; GROWTH FACTOR DELIVERY; SPATIAL REGULATION; TEMPORAL REGULATION;

BIOMATERIALS; TISSUE; TISSUE ENGINEERING;

BONE;

AGAROSE; ALGINIC ACID; APATITE; BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; CARBOXYMETHYLCELLULOSE; CHITOSAN; COLLAGEN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GELATIN; GROWTH DIFFERENTIATION FACTOR 5; GROWTH DIFFERENTIATION FACTOR 6; GROWTH FACTOR; HEPARIN; HYALURONIC ACID; HYDROXYAPATITE; OSTEOGENIC PROTEIN 1; OSTEOGENIN; PLATELET DERIVED GROWTH FACTOR; POLYGLACTIN; POLYLACTIC ACID; SOMATOMEDIN B; SOMATOMEDIN C; TITANIUM; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNINDEXED DRUG; VASCULOTROPIN;

BONE DEFECT; BONE REGENERATION; BONE TRANSPLANTATION; CELL DIVISION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FRACTURE HEALING; FRACTURE NONUNION; HISTOGENESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REOPERATION; REVIEW; TISSUE ENGINEERING;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE REGENERATION; DRUG DELIVERY SYSTEMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; TISSUE ENGINEERING;

EID: 84865303887     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.05.006     Document Type: Review

References (259)

1. Langer R., Vacanti J. Tissue engineering. Science 1993, 260:920-926.
2. Laurencin C., Khan Y., El-Amin S.F. Bone graft substitutes. Expert Rev. Med. Devices 2006, 3:49-57.
3. Bundesamt S. Bevölkerung Deutschlands bis 2050 2003.
4. Rodriguez-Merchan E.C., Forriol F. Nonunion: general principles and experimental data. Clin. Orthop. Relat. Res. 2004, 4-12.
5. Muscolo D.L., Ayerza M.A., Aponte-Tinao L.A. Massive allograft use in orthopedic oncology. Orthop. Clin. N. Am. 2006, 37. (65-+.).
6. DeCoster T.A., Gehlert R., Mikola E.A., Pirela-Cruz M.A. Management of posttraumatic segmental bone defects. J. Am. Acad. Orthop. Surg. 2004, 12:28-38.
7. Parikh S.N. Bone graft substitutes: past, present, future. J. Postgrad. Med. 2002, 48:142-148.
8. Eppley B.L., Pietrzak W.S., Blanton M.W. Allograft and alloplastic bone substitutes: a review of science and technology for the craniomaxillofacial surgeon. J. Craniofac. Surg. 2005, 16:981-989.
9. Peter S.J., Miller M.J., Yasko A.W., Yaszemski M.J., Mikos A.G. Polymer concepts in tissue engineering. J. Biomed. Mater. Res. 1998, 43:422-427.
10. Rose F.R.A.J., Oreffo R.O.C. Bone tissue engineering: hope vs. hype. Biochem. Biophys. Res. Commun. 2002, 292:1-7.
11. Lieberman J.R., Daluiski A., Einhorn T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Br. 2002, 84-A:1032-1044.
12. Kitaori T., Ito H., Schwarz E.M., Tsutsumi R., Yoshitomi H., Oishi S., Nakano M., Fujii N., Nagasawa T., Nakamura T. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009, 60:813-823.
13. Guldberg R.E. Spatiotemporal delivery strategies for promoting musculoskeletal tissue regeneration. J. Bone Miner. Res. 2009, 24:1507-1511.
14. Tseng S.S., Lee M.A., Reddi A.H. Nonunions and potential of stem cells in fracture-healing. Bone 2010, 92-98.
15. Kimelman N., Pelled G., Gazit Z., Gazit D. Applications of gene therapy and adult stem cells in bone bioengineering. Regen. Med. 2006, 1:549-561.
16. Caplan A.I. New era of cell-based orthopedic therapies. Tissue Eng. Part B Rev. 2009, 15:195-200.
17. Biondi M., Ungaro F., Quaglia F., Netti P.A. Controlled drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 2008, 60:229-242.
18. Phillips J.E., Gersbach C.A., Garcia A.J. Virus-based gene therapy strategies for bone regeneration. Biomaterials 2007, 28:211-229.
19. Santos J.L., Pandita D., Rodrigues J., Pego A.P., Granja P.L., Tomas H. Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration. Curr. Gene Ther. 2011, 11:46-57.
20. Kofron M.D., Laurencin C.T. Bone tissue engineering by gene delivery. Adv. Drug Deliv. Rev. 2006, 58:555-576.
21. Partridge K.A., Oreffo R.O. Gene delivery in bone tissue engineering: progress and prospects using viral and nonviral strategies. Tissue Eng. 2004, 10:295-307.
22. Schugar R.C., Robbins P.D., Deasy B.M. Small molecules in stem cell self-renewal and differentiation. Gene Ther. 2008, 15:126-135.
23. Bonadio J. Tissue engineering via local gene delivery: update and future prospects for enhancing the technology. Adv. Drug Deliv. Rev. 2000, 44:185-194.
24. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J. Cell. Biochem. 2003, 88:873-884.
25. Marsell R., Einhorn T.A. The biology of fracture healing. Injury 2011, 42:551-555.
26. Willenegger H., Perren S.M., Schenk R. Primary and secondary healing of bone fractures. Chirurg 1971, 42:241-252.
27. Einhorn T.A. The cell and molecular biology of fracture healing. Clin. Orthop. Relat. Res. 1998, S7-S21.
28. Willie B.M., Petersen A., Schmidt-Bleek K., Cipitria A., Mehta M., Strube P., Lienau J., Wildemann B., Fratzl P., Duda G. Designing biomimetic scaffolds for bone regeneration: why aim for a copy of mature tissue properties if nature uses a different approach?. Soft Matter 2010, 6:4976-4987.
29. Epari D.R., Duda G.N., Thompson M.S. Mechanobiology of bone healing and regeneration: in vivo models. Proc. Inst. Mech. Eng. H 2010, 224:1543-1553.
30. Kolar P., Schmidt-Bleek K., Schell H., Gaber T., Toben D., Schmidmaier G., Perka C., Buttgereit F., Duda G.N. The early fracture hematoma and its potential role in fracture healing. Tissue Eng. Part B Rev. 2010, 16:427-434.
31. 2! See what HIF can do!. Ann. Rheum. Dis. 2005, 64:971-980.
32. Wan C., Gilbert S.R., Wang Y., Cao X.M., Shen X., Ramaswamy G., Jacobsen K.A., Alaql Z.S., Gerstenfeld L.C., Einhorn T.A., Eberhardt A.W., Deng L., Guldberg R.E., Clemens T.L. Role of hypoxia inducible factor-1alpha pathway in bone regeneration. J. Musculoskelet. Neuronal Interact. 2008, 8:323-324.
33. Wang Y., Wan C., Deng L., Liu X., Cao X., Gilbert S.R., Bouxsein M.L., Faugere M.C., Guldberg R.E., Gerstenfeld L.C., Haase V.H., Johnson R.S., Schipani E., Clemens T.L. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Invest. 2007, 117:1616-1626.
34. Wilson C.J., Kasper G., Schutz M.A., Duda G.N. Cyclic strain disrupts endothelial network formation on Matrigel. Microvasc. Res. 2009, 78:358-363.
35. Street J., Winter D., Wang J.H., Wakai A., McGuinness A., Redmond H.P. Is human fracture hematoma inherently angiogenic?. Clin. Orthop. Relat. Res. 2000, 224-237.
36. Raheja L.F., Genetos D.C., Wong A., Yellowley C.E. Hypoxic regulation of mesenchymal stem cell migration: the role of RhoA and HIF-1alpha. Cell Biol. Int. 2011, 35(10):981-989.
37. Kasper G., Ode A., Groothuis A., Glaeser J., Gaber T., Wilson C.J., Geissler S., Duda G.N. Validation of beta-actin used as endogenous control for gene expression analysis in mechanobiology studies: amendments. Stem Cells 2010, 28:633-634.
38. Kasper G., Mao L., Geissler S., Draycheva A., Trippens J., Kuhnisch J., Tschirschmann M., Kaspar K., Perka C., Duda G.N., Klose J. Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells 2009, 27:1288-1297.
39. Groothuis A., Duda G.N., Wilson C.J., Thompson M.S., Hunter M.R., Simon P., Bail H.J., van Scherpenzeel K.M., Kasper G. Mechanical stimulation of the pro-angiogenic capacity of human fracture haematoma: involvement of VEGF mechano-regulation. Bone 2010, 47:438-444.
40. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
41. Pneumaticos S.G., Triantafyllopoulos G.K., Basdra E.K., Papavassiliou A.G. Segmental bone defects: from cellular and molecular pathways to the development of novel biological treatments. J. Cell. Mol. Med. 2010, 14:2561-2569.
42. Cho T.J., Gerstenfeld L.C., Einhorn T.A. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J. Bone Miner. Res. 2002, 17:513-520.
43. Keramaris N.C., Calori G.M., Nikolaou V.S., Schemitsch E.H., Giannoudis P.V. Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 2008, 39(Suppl. 2):S45-S57.
44. Marsh D. Concepts of fracture union, delayed union, and nonunion. Clin Orthop Relat R 1998, S22-S30.
45. Pelissier P., Villars F., Mathoulin-Pelissier S., Bareille R., Lafage-Proust M.H., Vilamitjana-Amedee J. Influences of vascularization and osteogenic cells on heterotopic bone formation within a madreporic ceramic in rats. Plast. Reconstr. Surg. 2003, 111:1932-1941.
46. Ponte A.L., Marais E., Gallay N., Langonne A., Delorme B., Herault O., Charbord P., Domenech J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007, 25:1737-1745.
47. Gerstenfeld L.C., Cho T.J., Kon T., Aizawa T., Tsay A., Fitch J., Barnes G.L., Graves D.T., Einhorn T.A. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J. Bone Miner. Res. 2003, 18:1584-1592.
48. Gerstenfeld L.C., Cho T.J., Kon T., Aizawa T., Cruceta J., Graves B.D., Einhorn T.A. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs 2001, 169:285-294.
49. Epari D.R., Kassi J.P., Schell H., Duda G.N. Timely fracture-healing requires optimization of axial fixation stability. J. Bone Joint Surg. Am. 2007, 89:1575-1585.
50. Epari D.R., Schell H., Bail H.J., Duda G.N. Instability prolongs the chondral phase during bone healing in sheep. Bone 2006, 38:864-870.
51. Trepczik B., Lienau J., Schell H., Epari D.R., Thompson M.S., Hoffmann J.E., Kadow-Romacker A., Mundlos S., Duda G.N. Endochondral ossification in vitro is influenced by mechanical bending. Bone 2007, 40:597-603.
52. Claes L., Wolf S., Augat P. Mechanical modification of callus healing. Chirurg 2000, 71:989-994.
53. Claes L., Blakytny R., Gockelmann M., Schoen M., Ignatius A., Willie B. Early dynamization by reduced fixation stiffness does not improve fracture healing in a rat femoral osteotomy model. J. Orthop. Res. 2009, 27:22-27.
54. Carter D.R., Beaupre G.S., Giori N.J., Helms J.A. Mechanobiology of skeletal regeneration. Clin. Orthop. Relat. Res. 1998, S41-S55.
55. Claes L.E., Heigele C.A. Magnitudes of local stress and strain along bony surfaces predict the course and type of fracture healing. J. Biomech. 1999, 32:255-266.
56. Prendergast P.J., Huiskes R., Søballe K. Biophysical stimuli on cells during tissue differentiation at implant interfaces. J. Biomech. 1997, 30:539-548.
57. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008, 29:155-192.
58. Boyce B.F., Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 2008, 473:139-146.
59. Kostenuik P.J., Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr. Pharm. Des. 2001, 7:613-635.
60. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
61. Perka C., Heller M., Wilke K., Taylor W.R., Haas N.P., Zippel H., Duda G.N. Surgical approach influences periprosthetic femoral bone density. Clin. Orthop. Relat. Res. 2005, 153-159.
62. Bosch P., Musgrave D., Lee J., Cummins J., Shuler T., Ghivizzani T., Evans T., Robbins T., Huard J. Osteoprogenitor cells within skeletal muscle. J. Orthop. Res. 2000, 18:933-944.
63. Rosen C.J., Ackert-Bicknell C., Rodriguez J.P., Pino A.M. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit. Rev. Eukaryot. Gene 2009, 19:109-124.
64. Harry L., Sandison A., Pearse M., Paleolog E., Nanchahal J. Comparison of the vascularity of fasciocutaneous tissue and muscle for coverage of open tibial fractures. Plast. Reconstr. Surg. 2009, 124:1211-1219.
65. Kumar S., Wan C., Ramaswamy G., Clemens T.L., Ponnazhagan S. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. Mol. Ther. 2010, 18:1026-1034.
66. Liu R., Birke O., Morse A., Peacock L., Mikulec K., Little D., Schindeler A. Myogenic progenitors contribute to open but not closed fracture repair. BMC Musculoskelet. Disord. 2011, 12:288.
67. Schell H., Thompson M.S., Bail H.J., Hoffmann J.E., Schill A., Duda G.N., Lienau J. Mechanical induction of critically delayed bone healing in sheep: radiological and biomechanical results. J. Biomech. 2008, 41:3066-3072.
68. Mehta M., Schell H., Schwarz C., Peters A., Schmidt-Bleek K., Ellinghaus A., Bail H.J., Duda G.N., Lienau J. A 5-mm femoral defect in female but not in male rats leads to a reproducible atrophic non-union. Arch. Orthop. Trauma Surg. 2011, 131:121-129.
69. Willie B., Adkins K., Zheng X., Simon U., Claes L. Mechanical characterization of external fixator stiffness for a rat femoral fracture model. J. Orthop. Res. 2009, 27:687-693.
70. Kratzel C., Bergmann C., Duda G., Greiner S., Schmidmaier G., Wildemann B. Characterization of a rat osteotomy model with impaired healing. BMC Musculoskelet. Disord. 2008, 9:135.
71. Peters A., Schell H., Bail H.J., Hannemann M., Schumann T., Duda G.N., Lienau J. Standard bone healing stages occur during delayed bone healing, albeit with a different temporal onset and spatial distribution of callus tissues. Histol. Histopathol. 2010, 25:1149-1162.
72. Schmidt-Bleek K., Schell H., Schulz N., Hoff P., Perka C., Buttgereit F., Volk H.D., Lienau J., Duda G.N. Inflammatory phase of bone healing initiates the regenerative healing cascade. Cell Tissue Res. 2012, 347(3):567-573.
73. Lienau J., Schmidt-Bleek K., Peters A., Haschke F., Duda G.N., Perka C., Bail H.J., Schutze N., Jakob F., Schell H. Differential regulation of blood vessel formation between standard and delayed bone healing. J. Orthop. Res. 2009, 27:1133-1140.
74. Lienau J., Schmidt-Bleek K., Peters A., Weber H., Bail H.J., Duda G.N., Perka C., Schell H. Insight into the molecular pathophysiology of delayed bone healing in a sheep model. Tissue Eng. Part A 2010, 16:191-199.
75. Einhorn T.A., Lane J.M., Burstein A.H., Kopman C.R., Vigorita V.J. The healing of segmental bone defects induced by demineralized bone matrix. A radiographic and biomechanical study. J. Bone Joint Surg. Am. 1984, 66:274-279.
76. Theos C., Koulouvaris P., Kottakis S., Demertzis N. Reconstruction of tibia defects by ipsilateral vascularized fibula transposition. Arch. Orthop. Trauma Surg. 2008, 128:179-184.
77. Perka C., Schultz O., Spitzer R.S., Lindenhayn K., Burmester G.R., Sittinger M. Segmental bone repair by tissue-engineered periosteal cell transplants with bioresorbable fleece and fibrin scaffolds in rabbits. Biomaterials 2000, 21:1145-1153.
78. Lane J.M., Tomin E., Bostrom M.P. Biosynthetic bone grafting. Clin. Orthop. Relat. Res. 1999, S107-S117.
79. Han D., Liu W., Ao Q., Wang G. Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix. Med. Hypotheses 2008, 71:374-378.
80. Haidar Z.S., Hamdy R.C., Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery. Biotechnol. Lett. 2009, 31:1817-1824.
81. Frost H.M. A determinant of bone architecture. The minimum effective strain. Clin. Orthop. Relat. Res. 1983, 286-292.
82. Griffin X.L., Smith C.M., Costa M.L. The clinical use of platelet-rich plasma in the promotion of bone healing: a systematic review. Injury 2009, 40:158-162.
83. Calori G.M., Tagliabue L., Gala L., d'Imporzano M., Peretti G., Albisetti W. Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients. Injury 2008, 39:1391-1402.
84. Sarkar M.R., Augat P., Shefelbine S.J., Schorlemmer S., Huber-Lang M., Claes L., Kinzl L., Ignatius A. Bone formation in a long bone defect model using a platelet-rich plasma-loaded collagen scaffold. Biomaterials 2006, 27:1817-1823.
85. Mountziaris P.M., Spicer P.P., Kasper F.K., Mikos A.G. Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng. Part B Rev. 2011, 17(6):393-402.
86. Peng H., Wright V., Usas A., Gearhart B., Shen H.C., Cummins J., Huard J. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J. Clin. Invest. 2002, 110:751-759.
87. Geiger F., Bertram H., Berger I., Lorenz H., Wall O., Eckhardt C., Simank H.G., Richter W. Vascular endothelial growth factor gene-activated matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J. Bone Miner. Res. 2005, 20:2028-2035.
88. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.Q., Bunting S., Ferrara N., Symes J.F., Isner J.M. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 1994, 93:662-670.
89. Basmanav F.B., Kose G.T., Hasirci V. Sequential growth factor delivery from complexed microspheres for bone tissue engineering. Biomaterials 2008, 29:4195-4204.
90. Oest M.E., Dupont K.M., Kong H.J., Mooney D.J., Guldberg R.E. Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects. J. Orthop. Res. 2007, 25:941-950.
91. Schmidmaier G., Wildemann B., Cromme F., Kandziora F., Haas N.P., Raschke M. Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: a biomechanical and histological study in rats. Bone 2002, 30:816-822.
92. Schmidmaier G., Wildemann B., Ostapowicz D., Kandziora F., Stange R., Haas N.P., Raschke M. Long-term effects of local growth factor (IGF-I and TGF-beta 1) treatment on fracture healing - a safety study for using growth factors. J. Orthop. Res. 2004, 22:514-519.
93. Dupoirieux L., Pohl J., Hanke M., Pourquier D. A preliminary report on the effect of dimeric rhGDF-5 and its monomeric form rhGDF-5C465A on bone healing of rat cranial defects. J. Craniomaxillofac. Surg. 2009, 37:30-35.
94. Yoshimoto T., Yamamoto M., Kadomatsu H., Sakoda K., Yonamine Y., Izumi Y. Recombinant human growth/differentiation factor-5 (rhGDF-5) induced bone formation in murine calvariae. J. Periodontal Res. 2006, 41:140-147.
95. Yonamine Y., Matsuyama T., Sonomura T., Takeuchi H., Furuichi Y., Uemura M., Izumi Y., Noguchi K. Effectable application of vascular endothelial growth factor to critical sized rat calvaria defects. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 109:225-231.
96. Quarto R., Mastrogiacomo M., Cancedda R., Kutepov S.M., Mukhachev V., Lavroukov A., Kon E., Marcacci M. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med. 2001, 344:385-386.
97. Peters A., Toben D., Lienau J., Schell H., Bail H.J., Matziolis G., Duda G.N., Kaspar K. Locally applied osteogenic predifferentiated progenitor cells are more effective than undifferentiated mesenchymal stem cells in the treatment of delayed bone healing. Tissue Eng. Part A 2009, 15:2947-2954.
98. Zhang X., Awad H.A., O'Keefe R.J., Guldberg R.E., Schwarz E.M. A perspective: engineering periosteum for structural bone graft healing. Clin. Orthop. Relat. Res. 2008, 466:1777-1787.
99. Stangenberg L., Schaefer D.J., Buettner O., Ohnolz J., Mobest D., Horch R.E., Stark G.B., Kneser U. Differentiation of osteoblasts in three-dimensional culture in processed cancellous bone matrix: quantitative analysis of gene expression based on real-time reverse transcription-polymerase chain reaction. Tissue Eng. 2005, 11:855-864.
100. Kadiyala S., Jaiswal N., Bruder S.P. Culture-expanded, bone marrow-derived mesenchymal stem cells can regenerate a critical-sized segmental bone defect. Tissue Eng. 1997, 3:173-185.
101. Mooney D.J., Vandenburgh H. Cell delivery mechanisms for tissue repair. Cell Stem Cell 2008, 2:205-213.
102. Tayalia P., Mooney D.J. Controlled growth factor delivery for tissue engineering. Adv. Mater. (Deerfield Beach, Fla.) 2009, 21:3269-3285.
103. Chen R.R., Mooney D.J. Polymeric growth factor delivery strategies for tissue engineering. Pharm. Res. 2003, 20:1103-1112.
104. Discher D.E., Mooney D.J., Zandstra P.W. Growth factors, matrices, and forces combine and control stem cells. Science (New York, N.Y.) 2009, 324:1673-1677.
105. Sands R.W., Mooney D.J. Polymers to direct cell fate by controlling the microenvironment. Curr. Opin. Biotechnol. 2007, 18:448-453.
106. Langer R.S., Peppas N.A. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 1981, 2:201-214.
107. Stefani C.M., Machado M.A., Sallum E.A., Sallum A.W., Toledo S., Nociti F.H. Platelet-derived growth factor/insulin-like growth factor-1 combination and bone regeneration around implants placed into extraction sockets: a histometric study in dogs. Implant Dent. 2000, 9:126-131.
108. Mooney D.J., Baldwin D.F., Suh N.P., Vacanti L.P., Langer R. Novel approach to fabricate porous sponges of poly(d, l-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials 1996, 17:1417-1422.
109. Yoneda A., Asada M., Oda Y., Suzuki M., Imamura T. Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity. Nat. Biotechnol. 2000, 18:641-644.
110. Suzuki Y., Tanihara M., Suzuki K., Saitou A., Sufan W., Nishimura Y. Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo. J. Biomed. Mater. Res. 2000, 50:405-409.
111. Slaughter B.V., Khurshid S.S., Fisher O.Z., Khademhosseini A., Peppas N.A. Hydrogels in regenerative medicine. Adv. Mater. 2009, 21:3307-3329.
112. Amende M.T., Hariharan D., Peppas N.A. Factors influencing drug and protein-transport and release from ionic hydrogels. React. Polym. 1995, 25:127-137.
113. Pillay V., Danckwerts M.P., Muhidinov Z., Fassihi R. Novel modulation of drug delivery using binary zinc-alginate-pectinate polyspheres for zero-order kinetics over several days: experimental design strategy to elucidate the crosslinking mechanism. Drug Dev. Ind. Pharm. 2005, 31:191-207.
114. Winn S.R., Uludag H., Hollinger J.O. Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv. Drug Deliv. Rev. 1998, 31:303-318.
115. Uludag H., D'Augusta D., Golden J., Li J., Timony G., Riedel R., Wozney J.M. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J. Biomed. Mater. Res. 2000, 50:227-238.
116. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur. J. Biochem. 1996, 237:295-302.
117. Winn S.R., Uludag H., Hollinger J.O. Carrier systems for bone morphogenetic proteins. Clin. Orthop. Relat. Res. 1999, S95-S106.
118. Riley E.H., Lane J.M., Urist M.R., Lyons K.M., Lieberman J.R. Bone morphogenetic protein-2: biology and applications. Clin. Orthop. Relat. Res. 1996, 39-46.
119. Kirker-Head C.A. Potential applications and delivery strategies for bone morphogenetic proteins. Adv. Drug Deliv. Rev. 2000, 43:65-92.
120. Li G., Bouxsein M.L., Luppen C., Li X.J., Wood M., Seeherman H.J., Wozney J.M., Simpson H. Bone consolidation is enhanced by rhBMP-2 in a rabbit model of distraction osteogenesis. J. Orthop. Res. 2002, 20:779-788.
121. Wozney J.M., Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin. Orthop. Relat. Res. 1998, 26-37.
122. Hubbell J.A., Lutolf M.R., Weber F.E., Schmoekel H.G., Schense J.C., Kohler T., Muller R. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat. Biotechnol. 2003, 21:513-518.
123. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. The spine journal : official journal of the North American Spine Society 2011, 11:471-491.
124. Buchowski J.M., Riew K.D., Nussenbaum B. In reference to acute airway obstruction in cervical spinal procedures with bone morphogenetic proteins. Laryngoscope 2011, 121:2501. (author reply 2502-2503).
125. Yaremchuk K.L., Toma M.S., Somers M.L., Peterson E. Acute airway obstruction in cervical spinal procedures with bone morphogenetic proteins. Laryngoscope 2010, 120:1954-1957.
126. Epstein N.E. Pros, cons, and costs of INFUSE in spinal surgery. Surg. Neurol. Int. 2011, 2:10.
127. Service R.F. Tissue engineers build new bone. Science 2000, 289:1498-1500.
128. Shields L.B., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., Shields C.B. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006, 31:542-547.
129. Li R., Stewart D.J., von Schroeder H.P., Mackinnon E.S., Schemitsch E.H. Effect of cell-based VEGF gene therapy on healing of a segmental bone defect. J. Orthopaed. Res. 2009, 27:8-14.
130. Street J., Bao M., deGuzman L., Bunting S., Peale F.V., Ferrara N., Steinmetz H., Hoeffel J., Cleland J.L., Daugherty A., van Bruggen N., Redmond H.P., Carano R.A., Filvaroff E.H. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9656-9661.
131. Kimoto T., Hosokawa R., Kubo T., Maeda M., Sano A., Akagawa Y. Continuous administration of basic fibroblast growth factor (FGF-2) accelerates bone induction on rat calvaria-an application of a new drug delivery system. J. Dent. Res. 1998, 77:1965-1969.
132. Ennett A.B., Kaigler D., Mooney D.J. Temporally regulated delivery of VEGF in vitro and in vivo. J. Biomed. Mater. Res. A 2006, 79:176-184.
133. Santo V.E., Frias A.M., Carida M., Cancedda R., Gomes M.E., Mano J.F., Reis R.L. Carrageenan-based hydrogels for the controlled delivery of PDGF-BB in bone tissue engineering applications. Biomacromolecules 2009, 10:1392-1401.
134. Chen F.M., Chen R., Wang X.J., Sun H.H., Wu Z.F. In vitro cellular responses to scaffolds containing two microencapsulated growth factors. Biomaterials 2009, 30:5215-5224.
135. Patel Z.S., Young S., Tabata Y., Jansen J.A., Wong M.E., Mikos A.G. Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 2008, 43:931-940.
136. Hasirci V., Yilgor P., Hasirci N. Sequential BMP-2/BMP-7 delivery from polyester nanocapsules. J. Biomed. Mater. Res. A 2010, 93A:528-536.
137. Oldham J.B., Lu L., Zhu X., Porter B.D., Hefferan T.E., Larson D.R., Currier B.L., Mikos A.G., Yaszemski M.J. Biological activity of rhBMP-2 released from PLGA microspheres. J. Biomech. Eng. T Asme 2000, 122:289-292.
138. Hong L., Tabata Y., Miyamoto S., Yamada K., Aoyama I., Tamura M., Hashimoto N., Ikada Y. Promoted bone healing at a rabbit skull gap between autologous bone fragment and the surrounding intact bone with biodegradable microspheres containing transforming growth factor-beta 1. Tissue Eng. 2000, 6:331-340.
139. Lu L.C., Yaszemski M.J., Mikos A.G. TGF-beta 1 release from biodegradable polymer microparticles: its effects on marrow stromal osteoblast function. J. Bone Joint Surg.-Am. 2001, 83A:S82-S91.
140. Hasirci V., Yilgor P., Tuzlakoglu K., Reis R.L., Hasirci N. Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering. Biomaterials 2009, 30:3551-3559.
141. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23:47-55.
142. Jeon O., Song S.J., Kang S.W., Putnam A.J., Kim B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(l-lactic-co-glycolic acid) scaffold. Biomaterials 2007, 28:2763-2771.
143. van de Wetering P., Metters A.T., Schoenmakers R.G., Hubbell J.A. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. J. Control. Release 2005, 102:619-627.
144. Lutolf M.P., Weber F.E., Schmoekel H.G., Schense J.C., Kohler T., Muller R., Hubbell J.A. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol. 2003, 21:513-518.
145. Kolambkar Y.M., Boerckel J.D., Dupont K.M., Bajin M., Huebsch N., Mooney D.J., Hutmacher D.W., Guldberg R.E. Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects. Bone 2011, 49:485-492.
146. Guldberg R.E., Oest M.E., Dupont K.M., Kong H.J., Mooney D.J. Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects. J. Orthop. Res. 2007, 25:941-950.
147. Ito Y. Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 2008, 4:46-56.
148. Fan V.H., Au A., Tamama K., Littrell R., Richardson L.B., Wright J.W., Wells A., Griffith L.G. Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells 2007, 25:1241-1251.
149. Pohl T.L.M., Boergermann J.H., Schwaerzer G.K., Knaus P., Cavalcanti-Adam E.A. Surface immobilization of bone morphogenetic protein 2 via a self-assembled monolayer formation induces cell differentiation. Acta Biomater. 2012, 8:772-780.
150. Karageorgiou V., Meinel L., Hofmann S., Malhotra A., Volloch V., Kaplan D. Bone morphogenetic protein-2 decorated silk fibroin films induce osteogenic differentiation of human bone marrow stromal cells. J. Biomed. Mater. Res. A 2004, 71A:528-537.
151. Weissleder R., Kelly K., Sun E.Y., Shtatland T., Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 2005, 23:1418-1423.
152. Alsberg E., Anderson K.W., Albeiruti A., Franceschi R.T., Mooney D.J. Cell-interactive alginate hydrogels for bone tissue engineering. J. Dent. Res. 2001, 80:2025-2029.
153. Gong J., Ito Y. Peptide immobilized on gold particles enhances cell growth. Cytotechnology 2008, 58:141-144.
154. Kiessling L.L., Gestwicki J.E., Strong L.E. Synthetic multivalent ligands as probes of signal transduction. Angew. Chem. Int. Ed. 2006, 45:2348-2368.
155. Ito Y., Zheng J., Imanishi Y., Yonezawa K., Kasuga M. Protein-free cell culture on an artificial substrate with covalently immobilized insulin. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3598-3601.
156. Tanihara M., Saito A., Suzuki Y., Ogata S., Ohtsuki C. Accelerated bone repair with the use of a synthetic BMP-2-derived peptide and bone-marrow stromal cells. J. Biomed. Mater. Res. A 2005, 72A:77-82.
157. Aono A., Hazama M., Notoya K., Taketomi S., Yamasaki H., Tsukuda R., Sasaki S., Fujisawa Y. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem. Biophys. Res. Commun. 1995, 210:670-677.
158. Bauer S., Park J., Pittrof A., Song Y.Y., von der Mark K., Schmuki P. Covalent functionalization of TiO(2) nanotube arrays with EGF and BMP-2 for modified behavior towards mesenchymal stem cells. Integr. Biol. (Camb.) 2011, 3:927-936.
159. Feito M.J., Lozano R.M., Alcaide M., Ramirez-Santillan C., Arcos D., Vallet-Regi M., Portoles M.T. Immobilization and bioactivity evaluation of FGF-1 and FGF-2 on powdered silicon-doped hydroxyapatite and their scaffolds for bone tissue engineering. J. Mater. Sci. Mater. Med. 2011, 22:405-416.
160. Evangelista M.B., Hsiong S.X., Fernandes R., Sampaio P., Kong H.J., Barrias C.C., Salema R., Barbosa M.A., Mooney D.J., Granja P.L. Upregulation of bone cell differentiation through immobilization within a synthetic extracellular matrix. Biomaterials 2007, 28:3644-3655.
161. Ceylan H., Kocabey S., Tekinay A.B., Guler M.O. Surface-adhesive and osteogenic self-assembled peptide nanofibers for bioinspired functionalization of titanium surfaces. Soft Matter 2012, 8:3929-3937.
162. Ratner B.D. The engineering of biomaterials exhibiting recognition and specificity. J. Mol. Recognit. 1996, 9:617-625.
163. Alsberg E., Kong H.J., Hirano Y., Smith M.K., Albeiruti A., Mooney D.J. Regulating bone formation via controlled scaffold degradation. J. Dent. Res. 2003, 82:903-908.
164. Comisar W.A., Kazmers N.H., Mooney D.J., Linderman J.J. Engineering RGD nanopatterned hydrogels to control preosteoblast behavior: a combined computational and experimental approach. Biomaterials 2007, 28:4409-4417.
165. Mooney D.J., Rowley J.A., Madlambayan G. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999, 20:45-53.
166. Kim J., Cao L., Shvartsman D., Silva E.A., Mooney D.J. Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett. 2011, 11:694-700.
167. Simmons C.A., Alsberg E., Hsiong S., Kim W.J., Mooney D.J. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 2004, 35:562-569.
168. Shah N.J., Macdonald M.L., Beben Y.M., Padera R.F., Samuel R.E., Hammond P.T. Tunable dual growth factor delivery from polyelectrolyte multilayer films. Biomaterials 2011, 32:6183-6193.
169. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 2001, 19:1029-1034.
170. Huang Y.-C., Kaigler D., Rice K.G., Krebsbach P.H., Mooney D.J. Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. J. Bone Miner. Res. 2005, 20:848-857.
171. Strobel C., Bormann N., Kadow-Romacker A., Schmidmaier G., Wildemann B. Sequential release kinetics of two (gentamicin and BMP-2) or three (gentamicin, IGF-I and BMP-2) substances from a one-component polymeric coating on implants. J. Control. Release 2011, 156:37-45.
172. Okuda T., Tominaga K., Kidoaki S. Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. J. Control. Release 2010, 143:258-264.
173. Lin C.C., Metters A.T. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug Deliv. Rev. 2006, 58:1379-1408.
174. Lee K.Y., Mooney D.J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 2012, 37:106-126.
175. Hao X., Silva E.A., Månsson-Broberg A., Grinnemo K.-H., Siddiqui A.J., Dellgren G., Wärdell E., Brodin L.Å., Mooney D.J., Sylvén C. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res. 2007, 75:178-185.
176. Moore N.M., Lin N.J., Gallant N.D., Becker M.L. Synergistic enhancement of human bone marrow stromal cell proliferation and osteogenic differentiation on BMP-2-derived and RGD peptide concentration gradients. Acta Biomater. 2011, 7:2091-2100.
177. Strayhorn C.L., Garrett J.S., Dunn R.L., Benedict J.J., Somerman M.J. Growth factors regulate expression of osteoblast-associated genes. J. Periodontol. 1999, 70:1345-1354.
178. Schmidmaier G., Wildemann B., Gabelein T., Heeger J., Kandziora F., Haas N.P., Raschke M. Synergistic effect of IGF-I and TGF-beta1 on fracture healing in rats: single versus combined application of IGF-I and TGF-beta1. Acta Orthop. Scand. 2003, 74:604-610.
179. Vonau R.L., Bostrom M.P., Aspenberg P., Sams A.E. Combination of growth factors inhibits bone ingrowth in the bone harvest chamber. Clin. Orthop. Relat. Res. 2001, 243-251.
180. Raiche A.T., Puleo D.A. In vitro effects of combined and sequential delivery of two bone growth factors. Biomaterials 2004, 25:677-685.
181. Huang Z., Ren P.G., Ma T., Smith R.L., Goodman S.B. Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Cytokine 2010, 51:305-310.
182. Wells A., Welsh J.B., Lazar C.S., Wiley H.S., Gill G.N., Rosenfeld M.G. Ligand-induced transformation by a noninternalizing epidermal growth-factor receptor. Science 1990, 247:962-964.
183. Yuen W.W., Du N.R., Chan C.H., Silva E.A., Mooney D.J. Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:17933-17938.
184. Ulijn R.V., Bibi N., Jayawarna V., Thornton P.D., Todd S.J., Mart R.J., Smith A.M., Gough J.E. Bioresponsive hydrogels. Mater. Today 2007, 10:40-48.
185. Lee K.Y., Peters M.C., Anderson K.W., Mooney D.J. Controlled growth factor release from synthetic extracellular matrices. Nature 2000, 408:998-1000.
186. Kost J., Langer R. Responsive polymeric delivery systems. Adv. Drug Deliv. Rev. 2001, 46:125-148.
187. Stubbe B.G., De Smedt S.C., Demeester J. "Programmed polymeric devices" for pulsed drug delivery. Pharm. Res. 2004, 21:1732-1740.
188. Zhao X., Kim J., Cezar C.A., Huebsch N., Lee K., Bouhadir K., Mooney D.J. Active scaffolds for on-demand drug and cell delivery. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:67-72.
189. Paliwal S., Mitragotri S. Ultrasound-induced cavitation: applications in drug and gene delivery. Expert Opin. Drug Deliv. 2006, 3:713-726.
190. Goldstein S.A. In vivo nonviral delivery factors to enhance bone repair. Clin. Orthop. Relat. Res. 2000, S113-S119.
191. Fang J., Zhu Y.Y., Smiley E., Bonadio J., Rouleau J.P., Goldstein S.A., McCauley L.K., Davidson B.L., Roessler B.J. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:5753-5758.
192. Bonadio J., Smiley E., Patil P., Goldstein S. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat. Med. 1999, 5:753-759.
193. Shea L.D., Smiley E., Bonadio J., Mooney D.J. DNA delivery from polymer matrices for tissue engineering. Nat. Biotechnol. 1999, 17:551-554.
194. Huang Y.C., Simmons C., Kaigler D., Rice K.G., Mooney D.J. Bone regeneration in a rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for bone morphogenetic protein-4 (BMP-4). Gene Ther. 2005, 12:418-426.
195. Endo M., Kuroda S., Kondo H., Maruoka Y., Ohya K., Kasugai S. Bone regeneration by modified gene-activated matrix: effectiveness in segmental tibial defects in rats. Tissue Eng. 2006, 12:489-497.
196. Jang J.H., Houchin T.L., Shea L.D. Gene delivery from polymer scaffolds for tissue engineering. Expert Rev. Med. Devices 2004, 1:127-138.
197. Kong H.J., Liu J., Riddle K., Matsumoto T., Leach K., Mooney D.J. Non-viral gene delivery regulated by stiffness of cell adhesion substrates. Nat. Mater. 2005, 4:460-464.
198. Jang J.H., Rives C.B., Shea L.D. Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection. Mol. Ther. 2005, 12:475-483.
199. Kawai M., Maruyama H., Bessho K., Yamamoto H., Miyazaki J., Yamamoto T. Simple strategy for bone regeneration with a BMP-2/7 gene expression cassette vector. Biochem. Biophys. Res. Commun. 2009, 390:1012-1017.
200. Wells D.J. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 2004, 11:1363-1369.
201. Aslan H., Zilberman Y., Arbeli V., Sheyn D., Matan Y., Liebergall M., Li J.Z., Helm G.A., Gazit D., Gazit Z. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng. 2006, 12:877-889.
202. Sheyn D., Kimelman-Bleich N., Pelled G., Zilberman Y., Gazit D., Gazit Z. Ultrasound-based nonviral gene delivery induces bone formation in vivo. Gene Ther. 2008, 15:257-266.
203. Burdick J.A., Mason M.N., Hinman A.D., Thorne K., Anseth K.S. Delivery of osteoinductive growth factors from degradable PEG hydrogels influences osteoblast differentiation and mineralization. J. Control. Release 2002, 83:53-63.
204. Bessho K., Carnes D.L., Cavin R., Ong J.L. Experimental studies on bone induction using low-molecular-weight poly (dl-lactide-co-glycolide) as a carrier for recombinant human bone morphogenetic protein-2. J. Biomed. Mater. Res. 2002, 61:61-65.
205. Tzafriri A.R., Lerner E.I., Flashner-Barak M., Hinchcliffe M., Ratner E., Parnas H. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres. Clin. Cancer Res. 2005, 11:826-834.
206. Kanjickal D.G., Lopina S.T. Modeling of drug release from polymeric delivery systems-a review. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:345-386.
207. Chen R.R., Silva E.A., Yuen W.W., Brock A.A., Fischbach C., Lin A.S., Guldberg R.E., Mooney D.J. Integrated approach to designing growth factor delivery systems. FASEB J. 2007, 21:3896-3903.
208. Baker M. Tissue models: a living system on a chip. Nature 2011, 471:661-665.
209. Webster A., Dyer C.E., Haswell S.J., Greenman J. A microfluidic device for tissue biopsy culture and interrogation. Anal. Methods-Uk 2010, 2:1005-1007.
210. Zahir N., Weaver V.M. Death in the third dimension: apoptosis regulation and tissue architecture. Curr. Opin. Genet. Dev. 2004, 14:71-80.
211. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science 2001, 294:1708-1712.
212. van Midwoud P.M., Merema M.T., Verpoorte E., Groothuis G.M.M. Microfluidics enables small-scale tissue-based drug metabolism studies with scarce human tissue. Jala-J. Lab. Autom. 2011, 16:468-476.
213. Yliperttula M., Chung B.G., Navaladi A., Manbachi A., Urtti A. High-throughput screening of cell responses to biomaterials. Eur. J. Pharm. Sci. 2008, 35:151-160.
214. Pernagallo S., Diaz-Mochon J.J. Polymer microarrays for cellular high-content screening. Methods Mol. Biol. 2011, 706:171-180.
215. Anderson D.G., Levenberg S., Langer R. Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. Nat. Biotechnol. 2004, 22:863-866.
216. Anderson D.G., Putnam D., Lavik E.B., Mahmood T.A., Langer R. Biomaterial microarrays: rapid, microscale screening of polymer-cell interaction. Biomaterials 2005, 26:4892-4897.
217. Snoeks T.J., Khmelinskii A., Lelieveldt B.P., Kaijzel E.L., Lowik C.W. Optical advances in skeletal imaging applied to bone metastases. Bone 2011, 48:106-114.
218. Kempen D.H., Yaszemski M.J., Heijink A., Hefferan T.E., Creemers L.B., Britson J., Maran A., Classic K.L., Dhert W.J., Lu L. Non-invasive monitoring of BMP-2 retention and bone formation in composites for bone tissue engineering using SPECT/CT and scintillation probes. J. Control. Release 2009, 134:169-176.
219. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
220. Lo Celso C., Fleming H.E., Wu J.W.W., Zhao C.X., Miake-Lye S., Fujisaki J., Cote D., Rowe D.W., Lin C.P., Scadden D.T. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 2009, 457. 92-U96.
221. Guldberg R.E., Ballock R.T., Boyan B.D., Duvall C.L., Lin A.S.P., Nagaraja S., Oest M., Phillips J., Porter B.D., Robertson G., Taylor W.R. Analyzing bone, blood vessels, and biomaterials with microcomputed tomography. IEEE Eng. Med. Biol. 2003, 22:77-83.
222. Kozloff K.M., Volakis L.I., Marini J.C., Caird M.S. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J. Bone Miner. Res. 2010, 25:1748-1758.
223. Borselli C., Cezar C.A., Shvartsman D., Vandenburgh H.H., Mooney D.J. The role of multifunctional delivery scaffold in the ability of cultured myoblasts to promote muscle regeneration. Biomaterials 2011, 32:8905-8914.
224. Chan G., Mooney D.J. New materials for tissue engineering: towards greater control over the biological response. Trends Biotechnol. 2008, 26:382-392.
225. Toben D., Schroeder I., El Khassawna T., Mehta M., Hoffmann J.E., Frisch J.T., Schell H., Lienau J., Serra A., Radbruch A., Duda G.N. Fracture healing is accelerated in the absence of the adaptive immune system. J. Bone Miner. Res. 2011, 26:113-124.
226. Ali O.A., Huebsch N., Cao L., Dranoff G., Mooney D.J. Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 2009, 8:151-158.
227. Devescovi V., Leonardi E., Ciapetti G., Cenni E. Growth factors in bone repair. Chir. Organi Mov. 2008, 92:161-168.
228. Kempen D.H.R., Creemers L.B., Alblas J., Lu L., Verbout A.J., Yaszemski M.J., Dhert W.J.a. Growth factor interactions in bone regeneration. Tissue Eng. Part B Rev. 2010, 16:551-566.
229. Deschaseaux F., Sensébé L., Heymann D. Mechanisms of bone repair and regeneration. Trends Mol. Med. 2009, 15:417-429.
230. Huang Z., Nelson E.R., Smith R.L., Goodman S.B. The sequential expression profiles of growth factors from osteoprogenitors [correction of osteroprogenitors] to osteoblasts in vitro. Tissue Eng. 2007, 13:2311-2320.
231. Ishibe T., Goto T., Kodama T., Miyazaki T., Kobayashi S., Takahashi T. Bone formation on apatite-coated titanium with incorporated BMP-2/heparin in vivo. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009, 108:867-875.
232. Johnson E.E., Urist M.R., Finerman G.A.M. Repair of segmental defects of the tibia with cancellous bone-grafts augmented with human-bone morphogenetic protein - a preliminary-report. Clin. Orthop. Relat. Res. 1988, 249-257.
233. Welch R.D., Jones A.L., Bucholz R.W., Reinert C.M., Tjia J.S., Pierce W.A., Wozney J.M., Li X.J. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J. Bone Miner. Res. 1998, 13:1483-1490.
234. Kandziora F., Bail H., Schmidmaier G., Schollmeier G., Scholz M., Knispel C., Hiller T., Pflugmacher R., Mittlmeier T., Raschke M., Haas N.P. Bone morphogenetic protein-2 application by a poly(d, l-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors. J. Neurosurg. 2002, 97:40-48.
235. Wulsten D., Glatt V., Ellinghaus A., Schmidt-Bleek K., Petersen A., Schell H., Lienau J., Sebald W., Ploger F., Seemann P., Duda G.N. Time kinetics of bone defect healing in response to Bmp-2 and Gdf-5 characterised by in vivo biomechanics. Eur Cells Mater 2011, 21:177-192.
236. Kolambkar Y.M., Dupont K.M., Boerckel J.D., Huebsch N., Mooney D.J., Hutmacher D.W., Guldberg R.E. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 2011, 32:65-74.
237. Ripamonti U., VandenHeever B., Sampath T.K., Tucker M.M., Rueger D.C., Reddi A.H. Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors 1996, 13. (273-&).
238. Stevenson S., Cunningham N., Toth J., Davy D., Reddi A.H. The effect of osteogenin (a bone morphogenetic protein) on the formation of bone in orthotopic segmental defects in rats. J. Bone Joint Surg. Am. 1994, 76A:1676-1687.
239. Forslund C., Aspenberg P. CDMP-2 induces bone or tendon-like tissue depending on mechanical stimulation. J. Orthop. Res. 2002, 20:1170-1174.
240. McKinney L., Hollinger J.O. A bone regeneration study: transforming growth factor-beta(1) and its delivery. J. Craniofac. Surg. 1996, 7:36-45.
241. Beck L.S., Wong R.L., DeGuzman L., Lee W.P., Ongpipattanakul B., Nguyen T.H. Combination of bone marrow and TGF-beta1 augment the healing of critical-sized bone defects. J. Pharm. Sci. 1998, 87:1379-1386.
242. Critchlow M.A., Bland Y.S., Ashhurst D.E. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone 1995, 16:521-527.
243. Steffen T., Stoll T., Arvinte T., Schenk R.K. Porous tricalcium phosphate and transforming growth factor used for anterior spine surgery. Eur. Spine J. 2001, 10:S132-S140.
244. Thaller S.R., Dart A., Tesluk H. The effects of insulin-like growth factor-1 on critical-size calvarial defects in Sprague-Dawley rats. Ann. Plast. Surg. 1993, 31:429-433.
245. Meinel L., Zoidis E., Zapf J., Hassa P., Hottiger M.O., Auer J.A., Schneider R., Gander B., Luginbuehl V., Bettschart-Wolfisberger R., Illi O.E., Merkle H.P., von Rechenberg B. Localized insulin-like growth factor I delivery to enhance new bone formation. Bone 2003, 33:660-672.
246. Raschke M., Wildemann B., Inden P., Bail H., Flyvbjerg A., Hoffmann J., Haas N.P., Schmidmaier G. Insulin-like growth factor-1 and transforming growth factor-beta1 accelerates osteotomy healing using polylactide-coated implants as a delivery system: a biomechanical and histological study in minipigs. Bone 2002, 30:144-151.
247. Toung J.S., Ogle R.C., Morgan R.F., Lindsey W.H. Insulinlike growth factor 1- and 2-augmented collagen gel repair of facial osseous defects. Arch. Otolaryngol. Head Neck Surg. 1999, 125:451-455.
248. Komaki H., Tanaka T., Chazono M., Kikuchi T. Repair of segmental bone defects in rabbit tibiae using a complex of beta-tricalcium phosphate, type I collagen, and fibroblast growth factor-2. Biomaterials 2006, 27:5118-5126.
249. Radomsky M.L., Aufdemorte T.B., Swain L.D., Fox W.C., Spiro R.C., Poser J.W. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J. Orthop. Res. 1999, 17:607-614.
250. Murakami S., Takayama S., Kitamura M., Shimabukuro Y., Yanagi K., Ikezawa K., Saho T., Nozaki T., Okada H. Recombinant human basic fibroblast growth factor (bFGF) stimulates periodontal regeneration in class II furcation defects created in beagle dogs. J. Periodontal Res. 2003, 38:97-103.
251. Cuevas P., dePaz V., Cuevas B., MarinMartinez J., PiconMolina M., FernandezPereira A., GimenezGallego G. Osteopromotion for cranioplasty: an experimental study in rats using acidic fibroblast growth factor. Surg. Neurol. 1997, 47:242-246.
252. Nash T.J., Howlett C.R., Martin C., Steele J., Johnson K.A., Hicklin D.J. Effect of platelet-derived growth-factor on tibial osteotomies in rabbits. Bone 1994, 15:203-208.
253. Lee Y.M., Park Y.J., Lee S.J., Ku Y., Han S.B., Klokkevold P.R., Chung C.P. The bone regenerative effect of platelet-derived growth factor-BB delivered with a chitosan/tricalcium phosphate sponge carrier. J. Periodontol. 2000, 71:418-424.
254. Kaigler D., Wang Z., Horger K., Mooney D.J., Krebsbach P.H. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J. Bone Miner. Res. 2006, 21:735-744.
255. Oest M.E., Dupont K.M., Kong H.J., Mooney D.J., Guldberg R.E. Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects. J. Orthop. Res. 2007, 25:941-950.
256. Si X., Jln Y., Yang L. Induction of new bone by ceramic bovine bone with recombinant human bone morphogenetic protein 2 and transforming growth factor β. Int. J. Oral Maxillofac. Surg. 1998, 27:310-314.
257. Ripamonti U., Duneas N., VandenHeever B., Bosch C., Crooks J. Recombinant transforming growth factor-beta 1 induces endochondral bone in the baboon and synergizes with recombinant osteogenic protein-1 (bone morphogenetic protein-7) to initiate rapid bone formation. J. Bone Miner. Res. 1997, 12:1584-1595.
258. Young S., Patel Z.S., Kretlow J.D., Murphy M.B., Mountziaris P.M., Baggett L.S., Ueda H., Tabata Y., Jansen J.A., Wong M., Mikos A.G. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng. Part A 2009, 15:2347-2362.
259. Kempen D.H.R., Lu L.C., Heijink A., Hefferan T.E., Creemers L.B., Maran A., Yaszemski M.J., Dhert W.J.A. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials 2009, 30:2816-2825.